PKD Clinical and Translational Core Study

Launched by UNIVERSITY OF MARYLAND, BALTIMORE · Jun 5, 2013

Keywords

ClinConnect Summary

The PKD Clinical and Translational Core Study is a research trial focused on understanding and finding new treatments for autosomal dominant polycystic kidney disease (ADPKD), a condition that causes fluid-filled cysts to grow in the kidneys. The main goal of this study is to create a strong support system for researchers, making it easier to recruit and study a diverse group of patients with ADPKD. They plan to gather information from 350 patients in the Mid-Atlantic region, collect biological samples like blood and urine, and build a network of doctors to help with future studies.

To participate in this trial, you need to be at least 18 years old and have a confirmed diagnosis of ADPKD. You should also have reasonably healthy kidney function, meaning your kidneys are still working well enough. Unfortunately, people with advanced kidney disease, those on dialysis, or with certain other health conditions cannot take part. If you join the study, you can expect to undergo health assessments and contribute to important research that could lead to better treatments for ADPKD in the future. Your involvement could make a difference not only for yourself but for many others facing this condition.

Gender

ALL

Eligibility criteria

• Inclusion criteria:
• • Age 18 and older
• • ADPKD confirmed by genetic testing or ultrasound criteria using modified Ravine criteria: with family history:several cysts per kidney (3 by sonography, 5 if by computerized tomography or MRI)without family history: 10 cysts (by any radiologic method) per kidney and exclusion of other cystic kidney diseases
• • Ability to provide written informed consent prior to initiation of any study procedures and the ability in the opinion of the investigator to comply with all requirements of the study
• • Glomerular Filtration Rate (GFR) greater than 15ml/min/1.73m2
• Exclusion Criteria:
• • End Stage Renal Disease or presently on dialysis or a prior kidney transplant
• • --Pregnant, lactating, or intention to get pregnant in next 6 weeks
• • Another systemic disease such as cancer or lupus
• • Life expectancy less than 2 years
• • Current participation in a drug treatment trial
• • Non English speaking
• • Uncontrolled diabetes A1C 7.0 or more within 6 months of study visit; and/or on more than one oral hypoglycemic agent
• • Diabetic nephropathy